Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions
Executive Summary
France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.
You may also be interested in...
AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake
Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.
Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC
Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.
Chastened Innate Returns Lumoxiti Rights To AZ
The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.